文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

减低剂量预处理单倍型外周血造血干细胞移植治疗50岁以上恶性血液肿瘤的临床研究

[Clinical research of HLA-haploidentical peripheral hematopoietic stem cell transplantation following reduced intensity conditioning regimen with hematological malignancy patients over 50 years old].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2019-01-01

该研究纳入18例50岁以上恶性血液肿瘤患者,采用FAB+rATG减低剂量预处理方案行单倍型外周血造血干细胞移植。2年总生存率为72.6%,无病生存率为63.7%,Ⅱ~Ⅳ度急性GVHD发生率为35.4%。结论认为该方案对此类患者可获得较好疗效。

要点

  • 50岁以上恶性血液肿瘤患者行RIC-haplo-PBSCT,2年OS为72.6%,DFS为63.7%。
  • Ⅱ~Ⅳ度急性GVHD发生率为35.4%,Ⅲ/Ⅳ度为13.8%,2年慢性GVHD累积发生率为38.2%。
  • 2年累积复发率为31.2%,非复发死亡率为12.5%。

核心结论

  • RIC-haplo-PBSCT方案治疗50岁以上恶性血液肿瘤患者可获得较好的疗效。

研究设计与样本

  • 研究纳入18例50岁以上恶性血液肿瘤患者,男8例、女10例,中位年龄52(50~66)岁。
  • 疾病类型包括AML 8例、CML 2例、MDS 5例、ALL 2例、ANKL 1例。
  • 所有患者接受FAB+rATG减低剂量预处理方案,输注供者高剂量非去T细胞外周血造血干细胞,并应用强化GVHD预防及感染防控措施。

主要发现

  • 移植后15天,16例患者获得完全供者嵌合;其中1例于移植后1个月发生移植排斥,另2例15天为混合嵌合、30天转为完全受体嵌合。
  • 急性GVHD累积发生率为61.1%(95%CI 49.6%~72.6%),Ⅱ~Ⅳ度为35.4%(95%CI 21.1%~49.7%),Ⅲ/Ⅳ度为13.8%(95%CI 4.7%~22.9%)。
  • 2年慢性GVHD累积发生率为38.2%(95%CI 25.5%~50.9%),未发生广泛型慢性GVHD。
  • 中位随访14.5(3~44)个月,2年总生存率为72.6%(95%CI 60.1%~85.1%),无病生存率为63.7%(95%CI 49.2%~78.2%)。
  • 2年累积复发率为31.2%(95%CI 16.5%~45.9%),非复发死亡率为12.5%(95%CI 4.2%~20.8%)。

临床怎么用

  • 对于50岁以上无全相合供者的恶性血液肿瘤患者,可考虑采用FAB+rATG减低剂量预处理联合单倍型外周血造血干细胞移植。
  • 移植后需强化GVHD预防和感染防控,并密切监测嵌合状态及GVHD发生情况。

局限性

  • 研究为单中心小样本(18例)回顾性分析,随访时间较短(中位14.5个月),结论需更大样本及更长随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the efficacy of HLA-haploidentical peripheral hematopoietic stem cell transplantation (haplo-PBSCT) following reduced intensity conditioning (RIC) regimen to treat the patients with hematological malignancies who were older than 50 years old. Methods: Eighteen patients with hematological malignancies over 50 years were enrolled, including 8 male and 10 female patients. The median age of all patients was 52 (range: 50-66) years. Of them, 8 patients had acute myeloid leukemia (AML) , 2 chronic myelocytic leukemia (CML) , 5 myelodysplastic syndrome (MDS) , 2 acute lymphoblastic leukemia (ALL) , and 1 aggressive natural killer cell leukemia (ANKL) . All patients received fludarabine, cytarabine and melphalan with rabbit anti-human thymocyte globulin (FAB+rATG regimen) and transplanted with high dose non-T cell-depleted peripheral hematopoietic stem cells from donors. Enhanced graft versus host disease (GVHD) prophylaxis and infection prevention were administered. Results: Fifteen days after transplantation, 16 patients achieved complete donor chimerism. One of them rejected the donor graft completely at thirty days after transplantation, and the other 2 patients had mixed chimerism 15 days after transplantation and converted to complete recipient chimerism at 30 days after transplantation. The cumulative incidence of acute GVHD (aGVHD) was 61.1% (95%CI49.6%-72.6%) . The incidence of grade Ⅱ-Ⅳ aGVHD was 35.4% (95%CI 21.1%-49.7%) , whereas grade III-IV was 13.8% (95%CI 4.7%-22.9%) . The 2-year cumulative incidence of chronic GVHD (cGVHD) rate was estimated at 38.2% (95%CI 25.5%-50.9%) . Patients were followed-up for a median of 14.5 months (range, 3-44 months) . The Kaplan Meier estimates of 2-year overall survival (OS) and disease-free survival (DFS) was 72.6% (95%CI 60.1%-85.1%) and 63.7% (95%CI 49.2%-78.2%) , respectively. The 2-year cumulative incidence of relapse and non-relapse-mortality (NRM) was 31.2% (95%CI 16.5%-45.9%) and 12.5% (95%CI 4.2%-20.8%) , respectively. Conclusion: RIC-haplo-PBSCT protocol can achieve better results in patients with hematologic malignancies over 50 years old. 目的: 分析减低剂量预处理单倍型外周血造血干细胞移植(RIC-haplo-PBSCT)治疗50岁以上恶性血液肿瘤患者的疗效。 方法: 18例50岁以上恶性血液肿瘤患者纳入研究,男8例,女10例,中位年龄52(50~66)岁;急性髓系白血病(AML)8例,慢性髓性白血病(CML)2例,骨髓增生异常综合征(MDS)5例,急性淋巴细胞白血病(ALL)2例,急性NK细胞白血病(ANKL)1例;采用FAB+ATG(氟达拉滨+阿糖胞苷+白消安+兔抗人胸腺细胞免疫球蛋白)减低剂量预处理方案,输注供者高剂量非去T细胞外周血造血干细胞(PBSC),应用强化移植物抗宿主病(GVHD)预防方案及感染防控措施。 结果: 16例患者在移植后15 d获得完全供者嵌合,其中1例在移植后1个月发生移植排斥,其余2例在移植后15 d为混合嵌合并于移植后1个月发生移植排斥。急性GVHD发生率为61.1%(95%CI 49.6%~72.6%),Ⅱ~Ⅳ度急性GVHD发生率为35.4%(95%CI 21.1%~49.7%),Ⅲ/Ⅳ度急性GVHD发生率为13.8%(95%CI 4.7%~22.9%)。2年慢性GVHD累积发生率为38.2%(95%CI 25.5%~50.9%),未发生广泛型慢性GVHD。中位随访14.5(3~44)个月,2年总生存率、无病生存率分别为72.6%(95%CI 60.1%~85.1%)、63.7%(95%CI 49.2%~78.2%),2年累积复发率为31.2%(95%CI 16.5%~45.9%),2年非复发死亡率为12.5%(95%CI 4.2%~20.8%)。 结论: RIC-haplo-PBSCT治疗50岁以上恶性血液肿瘤患者可获得较好的疗效。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu Y, Yuan HL, Duan XL, et al. [Clinical research of HLA-haploidentical peripheral hematopoietic stem cell transplantation following reduced intensity conditioning regimen with hematological malignancy patients over 50 years old]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31495134. doi:10.3760/cma.j.issn.0253-2727.2019.08.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。